No Data
No Data
Sailong Pharmaceutical Group (002898.SZ) has appointed Duan Daifeng as the company's vice president.
On July 19th, Gelonhui reported that Sailong Pharmaceutical Group (002898.SZ) announced the convening of the third meeting of the fourth board of directors on July 19, 2024, and approved the "Proposal on Appointing the Company's Vice President". Mr. Duan Daifeng was appointed as the company's vice president with the approval of the company's chairman, Mr. Cai Nangui, and the nomination committee of the board of directors. His term of office will be from the date of approval of this board of directors meeting to the expiration of the fourth board of directors.
Sailong Pharmaceutical's Anti-Cancer Chemotherapy Drug Gets Marketing Nod
Sailong Pharmaceutical Group (002898.SZ) received the approval notice for the application of market launch of the active pharmaceutical ingredient Fosaprepitant dimeglumine.
On July 1st, Gelunhui reported that Sailong Pharmaceutical Group (002898.SZ) announced its subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the "Chemical raw materials pharmaceutical application approval notice" for fosaprepitant dimeglumine issued by the National Medical Products Administration. Fosaprepitant dimeglumine is mainly used in combination with other antiemetic drugs for the prevention of acute and delayed nausea and vomiting in children over 6 months and adult patients with highly emetogenic antitumor chemotherapy drugs (HEC), including high-dose cisplatin, during initial and repeated use.
Sailong Pharmaceutical Group (002898.SZ) plans to distribute 0.2 yuan per share on a basis of 10 shares, with ex-right and ex-dividend dates on June 28.
Sailong Pharmaceutical Group (002898.SZ) announced its annual equity distribution for 2023: it plans to distribute 1.2 yuan in cash for every 10 shares to all shareholders...
Cailong Pharmaceutical (002898.SZ): Obtained a notice of approval for the marketing application of the chemical raw material propofol tenofovir fumarate
On June 3, Gelonghui Pharmaceutical (002898.SZ) announced that Hunan Sailong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently obtained the approval and issuance of the “Notice of Approval for the Marketing Application of Propofol fumarate Tenofovir” by the State Drug Administration. The main indications for prophenol tenofovir fumarate are: It is used to treat chronic hepatitis B in adults and adolescents.
Cailong Pharmaceutical (002898.SZ): Lysapirine received a notice of approval for the marketing application of chemical raw materials
Gelonghui, May 24 | Sailong Pharmaceutical (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for lysapillin approved and issued by the State Drug Administration. The main indications for lysapirine are: it is used to treat fever and mild to moderate pain.
No Data